Cargando…
Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256994/ https://www.ncbi.nlm.nih.gov/pubmed/37151116 http://dx.doi.org/10.1002/ueg2.12397 |
_version_ | 1785057225095512064 |
---|---|
author | Seeling, Katharina Sophie Hehl, Leonida Vell, Mara Sophie Rendel, Miriam Daphne Creasy, Kate Townsend Trautwein, Christian Mehler, David Marc Anton Keszthelyi, Daniel Schneider, Kai Markus Schneider, Carolin Victoria |
author_facet | Seeling, Katharina Sophie Hehl, Leonida Vell, Mara Sophie Rendel, Miriam Daphne Creasy, Kate Townsend Trautwein, Christian Mehler, David Marc Anton Keszthelyi, Daniel Schneider, Kai Markus Schneider, Carolin Victoria |
author_sort | Seeling, Katharina Sophie |
collection | PubMed |
description | BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality. METHODS: We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed (n = 20,603) and ICD‐10 diagnosed (n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients. RESULTS: In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]). CONCLUSION: Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients. |
format | Online Article Text |
id | pubmed-10256994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102569942023-06-11 Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study Seeling, Katharina Sophie Hehl, Leonida Vell, Mara Sophie Rendel, Miriam Daphne Creasy, Kate Townsend Trautwein, Christian Mehler, David Marc Anton Keszthelyi, Daniel Schneider, Kai Markus Schneider, Carolin Victoria United European Gastroenterol J Neurogastroenterology BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality. METHODS: We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed (n = 20,603) and ICD‐10 diagnosed (n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients. RESULTS: In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]). CONCLUSION: Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients. John Wiley and Sons Inc. 2023-05-07 /pmc/articles/PMC10256994/ /pubmed/37151116 http://dx.doi.org/10.1002/ueg2.12397 Text en © 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Neurogastroenterology Seeling, Katharina Sophie Hehl, Leonida Vell, Mara Sophie Rendel, Miriam Daphne Creasy, Kate Townsend Trautwein, Christian Mehler, David Marc Anton Keszthelyi, Daniel Schneider, Kai Markus Schneider, Carolin Victoria Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title | Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title_full | Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title_fullStr | Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title_full_unstemmed | Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title_short | Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study |
title_sort | comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: a phenome‐wide association study |
topic | Neurogastroenterology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256994/ https://www.ncbi.nlm.nih.gov/pubmed/37151116 http://dx.doi.org/10.1002/ueg2.12397 |
work_keys_str_mv | AT seelingkatharinasophie comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT hehlleonida comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT vellmarasophie comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT rendelmiriamdaphne comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT creasykatetownsend comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT trautweinchristian comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT mehlerdavidmarcanton comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT keszthelyidaniel comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT schneiderkaimarkus comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy AT schneidercarolinvictoria comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy |